Eli Lilly has announced highly positive topline results from the Phase 3 TRIUMPH-1 trial evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist.
Here are a few of the most striking takeaways from the newly released trial data:
Unprecedented Weight Loss: Participants taking the 12 mg dose lost an average of 70.3 lbs (28.3% of their body weight) over 80 weeks.
Continued Progress: In a 104-week extension study for individuals with a starting BMI of ≥35, participants achieved an average weight loss of 85.0 lbs (30.3%).
Cardiovascular Benefits: Beyond weight reduction, retatrutide showed significant improvements in key cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure.
Obesity is a complex neurometabolic disease, and these results suggest retatrutide could become a "highly impactful future tool" to transform patients' health trajectories.
Check out the full document for comprehensive details on the study's efficacy, dose escalations, and safety findings!
Full text: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
------------------------------
Clipper Young PharmD, MPH, BCGP, CDCES, BC-ADM, APh
Associate Professor and Clinical Pharmacist
Touro University California College of Osteopathic Medicine
Vallejo CA
------------------------------